D. E. Shaw & Co., Inc. Ocugen, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $381,297 - $591,011	-953,244 Reduced 87.27%	139,025 $55,000
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $491,521 - $961,196	1,092,269 New	1,092,269 $589,000
Q2 2022 Aug 15, 2022	SELL	$1.83 - $3.45 $62,779 - $118,355	-34,306 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.34 - $4.72 $80,276 - $161,924	34,306 New	34,306 $113,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.